Philips responds to ResMed study

Wednesday, May 20, 2015

MURRYSVILLE, Pa. – In the wake of a failed study by ResMed, Philips Respironics is recommending that clinicians not use Adaptive Servo-Ventilation (ASV) therapy, due to an increased risk of death in trial patients. ResMed announced May 13 that a phase III trial designed to assess whether treating moderate to severe predominant central sleep apnea with ASV therapy found a 10% per year mortality rate of trial patients, vs. 7.5% for the control group. Philips is working with ResMed to better understand study data, according to a release.